CAJ | 학술논문

目的：观察芳香化酶抑制剂耐药的晚期Luminal B型（ HER-2阳性）乳腺癌患者化疗临床获益后，行氟维司群联合曲妥珠单抗维持治疗的疗效及不良反应。方法11例芳香化酶抑制剂耐药的晚期Luminal B型（ HER-2阳性）乳腺癌患者化疗临床获益后，接受氟维司群内分泌治疗联合曲妥珠单抗靶向治疗维持。氟维司群500mg 肌肉注射，每月1次，第1个月的第14天加用500mg肌肉注射1次。曲妥珠单抗6mg/kg静滴，每3周重复。结果所有患者均可评价疗效，其中CR 1例，PR 1例，SD 5例，有效率（ RR）为18?2％，疾病控制率（ DCR）为63?6％。平均无疾病进展生存时间为8?4个月。毒副反应轻微，多为1～2级，无3级以上不良反应。结论芳香化酶抑制剂耐药的晚期Luminal B型（ HER-2阳性）乳腺癌患者，化疗有效后可行氟维司群内分泌治疗联合曲妥珠单抗靶向维持治疗，可延长其无疾病进展生存时间。
목적：관찰방향화매억제제내약적만기Luminal B형（ HER-2양성）유선암환자화료림상획익후，행불유사군연합곡타주단항유지치료적료효급불량반응。방법11례방향화매억제제내약적만기Luminal B형（ HER-2양성）유선암환자화료림상획익후，접수불유사군내분비치료연합곡타주단항파향치료유지。불유사군500mg 기육주사，매월1차，제1개월적제14천가용500mg기육주사1차。곡타주단항6mg/kg정적，매3주중복。결과소유환자균가평개료효，기중CR 1례，PR 1례，SD 5례，유효솔（ RR）위18?2％，질병공제솔（ DCR）위63?6％。평균무질병진전생존시간위8?4개월。독부반응경미，다위1～2급，무3급이상불량반응。결론방향화매억제제내약적만기Luminal B형（ HER-2양성）유선암환자，화료유효후가행불유사군내분비치료연합곡타주단항파향유지치료，가연장기무질병진전생존시간。
Objective To observe the efficacy and safety of Luminal B( HER-2 positive) advanced breast cancer patients who receive fulvestrant combined with trastuzumab after prior aromatase inhibitors and disease controlled by chemotherapy. Methods There were 11 advanced aromatase inhibitors Luminal B breast cancer patients who received fulvestrant plus trastuzumab as maintenane thera-py, after they benefited from palliative chemotherapy. Fulvestrant regimen was 500 mg every month plus 500 mg on day 14 of month 1 and trastuzumab regimen was 6mg/kg every 3 weeks. Results All patients were available for evaluation. Of the 11 patients, 1 case got complete response(CR), 1 case had partial response(PR) and 5 cases had stable disease(SD). The average PFS was 8?4 months. The objective response rate was 18?2% and disease control rate was 63?6%. The treatment was well tolerated and no severe adverse effects were observed. Conclusion The combination of fulvestrant and trastuzumab regimen is effective and tolerable in the treatment of advanced Luminal B( HER-2 positive) breast cancer patients who resistant to aromatase inhibitors after palliative chemotherapy to prolong the progression-free survival time.